Apellis Pharmaceuticals, Inc. (APLS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Apellis Pharmaceuticals, Inc. (APLS)
Company Performance

Current Price

as of Oct 16, 2024

$27.95

P/E Ratio

N/A

Market Cap

$3.4B

Description

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Metrics

Overview

  • HQWaltham, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerAPLS
  • Price$27.950.00%

Trading Information

  • Market Cap$3.40B
  • Float82.93%
  • Average Daily Volume (1m)3,183,278
  • Average Daily Volume (3m)2,026,403
  • EPS-$2.74

Company

  • Revenue$628.79M
  • Rev Growth (1yr)110.26%
  • Net Income-$37.66M
  • Gross Margin88.21%
  • EBITDA Margin-14.52%
  • EBITDA-$28.99M
  • EV$4.87B
  • EV/Revenue7.74
  • P/EN/A
  • P/S5.51
  • P/B12.87
Documents
SEC Filings
8-K (2024-08-08)
8-K (2024-06-05)
8-K (2024-05-14)
8-K (2024-02-27)
8-K (2024-01-22)
8-K (2024-01-08)
8-K (2023-12-14)
8-K (2023-12-01)
8-K (2023-11-01)
8-K (2023-10-05)
8-K (2023-08-29)
8-K (2023-08-22)
8-K (2023-07-31)
8-K (2023-07-17)
8-K (2023-06-01)
8-K (2023-03-15)
8-K (2023-02-24)
8-K (2023-01-09)
8-K (2023-01-05)
10-Q (2024-08-01)
10-Q (2024-05-07)
10-Q (2023-11-01)
10-Q (2023-07-31)
10-Q (2023-05-04)
10-K (2024-02-27)
10-K (2023-02-21)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Apellis Pharmaceuticals Q3 ($ 49.28, +0.62) (2023-11-01T17:07:04Z)
Apellis to present Phase 2 NOBLE Results of Pegcetacoplan in post-Transplant recurrence of primary IC-MPGN and C3G at Kidney Week ($48.18, 0.00) (2023-10-17T11:44:17Z)
Apellis reports preliminary Q3 U.S. net revenues of ~$74M for SYFOVRE (pegcetacoplan injection) ($37.62, 0.00) (2023-10-05T11:03:32Z)
Apellis Pharmaceuticals updated U.S. Prescribing Information for SYFOVRE - 8-K ($53.87, 0.00) (2023-12-01T13:44:06Z)
Apellis Pharmaceuticals ticks lower amid circulation of negative report published by Citron Research ($44.89, -1.94) (2023-11-06T15:02:01Z)
Apellis Pharmaceuticals reports Q3 EPS ($1.17) vs FactSet ($0.99) [13 est, ($1.15)-(0.77)] ($48.66, 0.00) (2023-11-01T11:10:29Z)
Apellis Pharmaceuticals presents data from GALE extension study of SYFOVRE at AAO annual meeting ($46.83, 0.00) (2023-11-04T22:13:54Z)
Apellis Pharmaceuticals initiated buy at Goldman Sachs ($46.99, 0.00) (2023-11-09T11:31:35Z)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-01)
Earnings Report (2023-07-31)